BioVie Clinical Data Unveils Bezisterim's Anti-Inflammatory Potential
![BioVie Clinical Data Unveils Bezisterim's Anti-Inflammatory Potential](https://investorshangout.com/images/blog/ihnews-BioVie%20Clinical%20Data%20Unveils%20Bezisterim%27s%20Anti-Inflammatory%20Potential.jpg)
BioVie Clinical Data Unveils Bezisterim's Anti-Inflammatory Potential
Bezisterim appears to possess broad homeostatic properties relevant to inflammation and human disorders related to aging.
Patients treated with bezisterim experienced age deceleration advantages compared to placebo, showing a compelling outcome in clinical studies.
The drug modulated DNA methylation of proinflammatory genes and facilitated the transition of M1 proinflammatory macrophages to M2 anti-inflammatory macrophages.
Furthermore, bezisterim was associated with significant gene control, exhibiting impressive results in pathways linked to neurodegenerative disorders and biological processes.
BioVie Inc. (NASDAQ: BIVI), a clinical-stage company dedicated to developing innovative drug therapies for neurological and neurodegenerative disorders, recently announced pivotal data during a presentation at the 11th Aging Research and Drug Discovery Meeting (ARDD 2024).
Presentation Overview
The presentation titled “Bezisterim Effects on Biological Age, Alzheimer’s Epigenetics, and Neurologic Assessments” provided comprehensive clinical data focusing on various analyses and measurements related to longevity and inflammation management.
Christopher L. Reading, BioVie’s Senior Vice President of the Alzheimer’s Disease Program, discussed the significance of the data. According to Cuong Do, BioVie’s President and CEO, clinical data revealed that patients treated with bezisterim enjoyed a two- to four-year age deceleration advantage over those receiving placebo. This was measured by various biological clocks, underscoring bezisterim's potential in addressing biological aging and chronic inflammation.
Understanding DNA Methylation
As individuals age, a natural phenomenon called DNA methylation can affect gene expression. This process involves the addition of methyl groups to DNA, influencing various genes' functions. The ARDD 2024 presentation highlighted bezisterim’s ability to modulate DNA methylation, exhibiting promising impacts.
Clinical Trial Insights
The extent of DNA methylation can be tracked using biological clocks that measure a person's biological age. Clinical trials revealed that bezisterim significantly impacted age deceleration when compared to placebo. Specifically, metrics such as the SkinBlood Clock and Inflammation Age Clock indicated substantial advantages for bezisterim-treated patients.
Additionally, DNA in blood primarily originates from monocytes, lymphocytes, and granulocytes. In the clinical trial, analyses showcased that bezisterim might support the progression of macrophages from an inflammatory state to a more anti-inflammatory condition.
Biological Pathways and Bezisterim
Clinical observations presented at ARDD 2024 illustrated how bezisterim influences inflammatory pathways. It potentially modulates methylation levels in genes responsible for producing inflammatory factors such as TNF? and IL6. This suggests a therapeutic avenue for managing chronic low-grade inflammation, which is believed to contribute to various diseases.
Moreover, bezisterim demonstrated a range of effects, including “fold enrichment” in pathways leading to diseases like Alzheimer’s and Parkinson’s diseases, alongside influencing biological processes related to senescence and apoptosis.
Future Directions and Research
Bezisterim (NE3107) represents a groundbreaking advancement as an oral, bioavailable, and BBB-permeable drug candidate. With potential applications for treating neurological disorders including Alzheimer’s and Parkinson’s diseases, ongoing research and clinical trials are pivotal for assessing efficacy and safety.
BioVie continues evaluating bezisterim’s role in combating conditions related to long COVID, focusing on alleviating symptoms such as cognitive dysfunction and fatigue.
About BioVie Inc.
BioVie Inc. (NASDAQ: BIVI) is advancing innovative therapies for significant health concerns in its pursuit of solutions for neurological disorders and advanced liver diseases. Their drug candidate bezisterim acts specifically to inhibit inflammatory activation pathways, showcasing the potential to improve patients' lives significantly.
The company is also pioneering a Phase 3 study for its Orphan drug candidate, BIV201, aimed at treating complications of chronic liver cirrhosis. BioVie is dedicated to addressing pressing health needs through advanced research and clinical applications.
Frequently Asked Questions
What is bezisterim?
Bezisterim (NE3107) is an orally bioavailable, BBB-permeable drug candidate being studied for its anti-inflammatory properties and potential to reduce symptoms of neurological disorders.
How does bezisterim impact inflammation?
Clinical data suggests that bezisterim modulates DNA methylation of genes related to inflammation, which may help transition macrophages from a pro-inflammatory to an anti-inflammatory state.
What were the key findings from the ARDD 2024 presentation?
The presentation highlighted bezisterim's ability to provide significant age deceleration advantages in clinical trials and its effect on proinflammatory gene methylation.
Is BioVie involved in any other research?
Yes, BioVie is conducting clinical studies on bezisterim for neurological disorders and is evaluating its Orphan drug candidate BIV201 for advanced liver disease.
How can I learn more about BioVie?
For additional information, please refer to BioVie's website or investor relations contact for inquiries regarding their ongoing research and developments.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Eli Lilly's Growth Potential: Insights on Tirzepatide
- Point Predictive Unveils IEValidate for Enhanced Verification
- Applied Systems Unveils Innovative Updates to Applied Pay
- Broadcom Unveils VMware Tanzu Platform 10 for Intelligent Apps
- HYCU R-Cloud™ Enhances Data Protection with Microsoft Entra ID
- Glucotrack Welcomes New VP of Clinical Operations
- Vera Bradley Unveils Vintage Capsule Collection with Urban Outfitters
- Arhaus Unveils Artisan-Crafted Fall 2024 Collection
- Janover Pro: Transforming Access to Commercial Lender Data
- SoundThinking Appoints Adan Pope as SVP of Data Science